SafeBoosC-III随机临床试验期间临床工作人员的基于网络培训与认证
SafeBoosC-III是一项在亚洲、欧洲和美国70个中心随机分配1601名极早产儿的实用性多国临床试验,评估脑氧饱和度监测指导的治疗。研究对工作人员实施基于网络的培训与认证项目,2347名工作人员中926名(39%)获得认证,完成评价的295名工作人员中83%评价项目总体良好、94%认为与临床实践相关。作者认为该培训认证项目可行,但仅少数中心达到80%认证率,未检测到对试验的影响。
要点
- 2347名工作人员中926名(39%)获得认证,仅少数中心认证率超过80%。
- 完成评价的295名工作人员中83%评价项目总体良好,94%认为与临床实践相关。
- 各中心认证率与因脑缺氧改变临床管理的频率、与干预效应的中心估计值均无相关性。
核心结论
- 尽管存在语言障碍和低预算,基于网络的培训与认证项目证明可行;仅少数中心达到80%的工作人员认证率,且未能检测到对试验的影响。
研究设计与样本
- SafeBoosC-III是一项实用性多国临床试验,在亚洲、欧洲和美国的70个中心随机分配1601名极早产儿,评估脑氧饱和度监测指导的治疗。
- 培训模块包括初始学习材料和基于病例的测验,测验对正确与错误答案均给出详细回应;模块涵盖试验介绍、脑氧饱和度监测、治疗指南、脑超声和良好临床实践。
- 介绍模块在在线平台提供八种语言版本,其他模块因需求不同而语言版本各异;完成模块后获得认证,与工作人员类别相关;培训非强制,主要研究者持续收到本地认证率报告以作激励。
主要发现
- 2347名工作人员中926名(39%)获得认证。
- 完成评价的295名工作人员中,83%评价项目总体良好,94%认为与临床实践相关。
- 各中心认证率不同:10个中心为0%,43个中心在0.1%至79.9%之间,17个中心超过80%。
- 各中心认证率与因脑缺氧改变临床管理的频率无相关性,与干预效应的中心特异性估计值也无相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文报告存在语言障碍和低预算。
- 仅少数中心达到80%的工作人员认证率。
- 未能检测到培训认证项目对试验的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SafeBoosC-III is a pragmatic, multinational clinical trial evaluating cerebral oximetry-guided treatment for extremely preterm infants. In total, 1601 infants were randomised across 70 sites in Asia, Europe, and USA. To enhance data quality and patient care, a web-based training program was implemented for staff. We now report on the processes. METHODS: All training modules consisted of initial learning material followed by a case-based quiz, with elaborate responses to correct as well as to wrong answers. Modules covered trial introduction, cerebral oximetry monitoring, treatment guidelines, cerebral ultrasound, and Good Clinical Practice. The introduction module was accessible in eight languages on an online platform, while language versions varied for other modules, due to different needs. Certification was earned upon module completion, relevant to the staff category. The training was not mandatory, but for motivational purposes, principal investigators continuously received local certification rate reports. RESULTS: A total of 926 out of 2347 staff (39%) obtained certification. Amongst 295 staff who completed the evaluation, 83% rated the program as overall good and 94% found it relevant to clinical practice. Sites exhibited varying certification rates, with 10 at 0%, 43 between 0.1 and 79.9%, and 17 exceeding 80%. There was no correlation between the rate of certification in individual sites and how often the clinical management was changed due to cerebral hypoxia nor a correlation to site-specific estimates of the intervention effect. CONCLUSION: Despite language barriers and a low budget, our web-based training and certification program proved feasible. Only a minority of sites reached 80% certification of staff and an impact on the trial could not be detected. TRIAL REGISTRATION: The SafeBoosC-III trial is registered at ClinicalTrials.gov NCT03770741. The first participant was randomised in June 2019 and recruitment was completed in December 2021.
引用
- Rasmussen MIS, Hansen ML, Peters C, et al. Web-based training and certification of clinical staff during the randomised clinical trial SafeBoosC-III. Trials. 2024. PMID: 39444031. doi:10.1186/s13063-024-08530-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。